This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Mycophenolate for Pulmonary Sarcoidosis

This study has been terminated.
Hoffmann-La Roche
Information provided by:
Medical University of South Carolina Identifier:
First received: December 5, 2005
Last updated: January 4, 2007
Last verified: January 2007
Corticosteroids are presently the drug of choice for the treatment of pulmonary sarcoidosis. However, corticosteroids are associated with many significant side effects. For this reason, it would be beneficial to find an alternative agent to corticosteroids for the treatment of pulmonary sarcoidosis. This study is an open label trial of mycophenolate for new onset pulmonary sarcoidosis. Patients are candidates for this study if they have biopsy proven pulmonary sarcoidosis and a vital capacity or FEV1 less than 80% of predicted. Patients must undergo bronchoscopy where not only is the diagnosis of pulmonary sarcoidosis required, but in addition, cells are obtained from bronchoalveolar lavage. If the patients are diagnosed with pulmonary sarcoidosis, they are placed on an initial dose of 500mg BID of mycophenolate for 1 week. If their blood counts are not affected on this dose and they have no significant symptoms that are thought to be drug related, then their dose is escalated to 1g BID for the remaining 9 weeks of the study (the total study drug therapy time is 10 weeks). The patients are followed with multiple study visits. At these visits blood tests are drawn to make sure that there are no significant side effects from mycophenolate. In addition, the patients have a history and physical performed to evaluate the clinical state of their sarcoidosis and to detect mycophenolate side effects. On completion of 10 weeks of mycophenolate therapy, the patients undergo a second bronchoscopy with bronchoalveolar lavage to obtain cells for analysis. The patients are evaluated with spirometry, measurements of shortness of breath (dyspnea), and a quality of life scale (SF36) at serial visits during their study. The primary endpoint of the study is improved, unchanged or worse FVC. It is hoped that this pilot study will suggest that mycophenolate is a reasonable treatment option for new onset pulmonary sarcoidosis.

Condition Intervention Phase
Pulmonary Sarcoidosis Drug: Mycophenolate Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Mycophenolate for Pulmonary Sarcoidosis

Resource links provided by NLM:

Further study details as provided by Medical University of South Carolina:

Estimated Enrollment: 20
Study Start Date: September 2003
Estimated Study Completion Date: August 2006

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

New acute pulmonary sarcoidosis defined as a FVC or FEV1 less than 80 percent of predicted plus symptoms of worsening dyspnea, cough, chest pain, or wheezing in patients without a prior history of pulmonary sarcoidosis. All such patients will also require bronchoscopy with transbronchial biopsy that demonstrates noncaseating granulomas of unknown cause. Such patients are usually treated for acute pulmonary sarcoidosis. The transbronchial biopsy specimens must have negative stains for mycobacteria and fungi.

> 18 years of age

Signing a written informed consent form.

Exclusion Criteria

  1. Previous history of an adverse reaction to mycophenolate.
  2. Current use of another immunosuppressive medication.
  3. History of active hepatitis or another significant liver disease with the exception of proven or presumed sarcoidosis of the liver.
  4. Previous history of skin cancer
  5. Active peptic ulcer disease
  6. Pregnant and/ or lactating female
  7. Serum creatinine > 2.0 mg/dl
  8. Serum bilirubin > 3.0 mg/dl
  9. WBC < 4,000/cu mm3
  10. Has demonstrated non-compliance in the past
  11. Current alcohol or drug abuse
  12. Evidence of significant sarcoidosis in extrapulmonary organs that requires therapy such that the mycophenolate doses could not be tapered if the pulmonary sarcoidosis was stable or improved.
  13. History of previous severe digestive system disease
  14. Patients taking azathioprine
  15. Patients taking cholestyramine or other drugs that affect enterohepatic recirculation
  16. Patients with Lesch-Nyhan or Kelley-Seegmiller syndrome
  17. Patients be willing not to receive live vaccines during the study
  18. Patients with phenylketonuria
  19. Patients with elevated serum transaminases or total bilirubin at baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00262132

United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
Hoffmann-La Roche
Principal Investigator: Marc A Judson, MD Medical University of South Carolina
  More Information Identifier: NCT00262132     History of Changes
Other Study ID Numbers: CEL401
HR 11031
Study First Received: December 5, 2005
Last Updated: January 4, 2007

Additional relevant MeSH terms:
Sarcoidosis, Pulmonary
Lymphoproliferative Disorders
Lymphatic Diseases
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Mycophenolic Acid
Mycophenolate mofetil
Antibiotics, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 23, 2017